---
layout: post
title: "Erosive Esophagitis: Developing Drugs for Treatment; Draft Guidance for Industry; Availability"
date: 2026-02-04 21:49:21 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-18001
original_published: 2025-09-17 00:00:00 +0000
significance: 8.00
---

# Erosive Esophagitis: Developing Drugs for Treatment; Draft Guidance for Industry; Availability

**Published:** February 04, 2026 21:49 UTC
**Source:** Federal Register
**Original Published:** September 17, 2025 00:00 UTC
**Document Number:** 2025-18001

## Summary

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Erosive Esophagitis: Developing Drugs for Treatment." The draft guidance details recommendations on clinical trials for drugs being developed for the healing of erosive esophagitis (EE) and maintenance of healed EE in adults, including considerations for eligibility criteria, trial design features, efficacy evaluations, and safety assessments.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/09/17/2025-18001/erosive-esophagitis-developing-drugs-for-treatment-draft-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2025-18001

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
